<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051527</url>
  </required_header>
  <id_info>
    <org_study_id>2019-24-NIS-Multicountry-3327</org_study_id>
    <nct_id>NCT05051527</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effectiveness of Legalon®</brief_title>
  <official_title>Observational, Single Arm, Prospective Study to Evaluate the Effectiveness of Legalon® in Addition to Diet and Exercise in Reducing Plasma Levels of Liver Enzymes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Meda Pharma S.p.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multinational, multicentre, prospective, non-interventional study (NIS) in&#xD;
      non-alcoholic fatty liver disease (NAFLD) patients with concomitant metabolic syndrome&#xD;
      treated with Legalon® combined with diet and exercise.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>effectiveness of Legalon®</measure>
    <time_frame>6 months</time_frame>
    <description>- To observe the effectiveness of Legalon® in addition to diet and exercise in lowering the plasma levels of liver enzymes in patients with non-alcoholic fatty liver disease (NAFLD) and concomitant metabolic syndrome</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">362</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease (NAFLD)</condition>
  <arm_group>
    <arm_group_label>Legalon®</arm_group_label>
    <description>Legalon® 140 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Legalon® 140 mg</intervention_name>
    <description>Legalon® 140 mg as per the Summary of Product Characteristics (SPC) and as per treating Investigator's decision</description>
    <arm_group_label>Legalon®</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with non-alcoholic fatty liver disease and concomitant metabolic syndrome&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Legalon® monotherapy prescribed by the treating Investigator according to the SPC,&#xD;
             independently from and within a 4-week window prior to enrolment into the study.&#xD;
&#xD;
          2. Male/female, 18 years of age and older&#xD;
&#xD;
          3. Able to provide informed consent&#xD;
&#xD;
          4. Available baseline blood results not older than 4 weeks from inclusion, with elevated&#xD;
             plasma level of at least one liver enzyme with respect to normal ranges of local&#xD;
             laboratory (&gt;1 UNL)&#xD;
&#xD;
          5. NAFLD diagnosed by ultrasonography according to the protocol by Hamaguchi or by the&#xD;
             protocol of Ballestri&#xD;
&#xD;
          6. Presence of metabolic syndrome, defined as the presence of at least 3 out of 5 of the&#xD;
             following:&#xD;
&#xD;
               1. Central obesity (for Asian population, waist circumference ≥90 cm in males, ≥80&#xD;
                  cm in females)&#xD;
&#xD;
               2. Insulin resistance (fasting blood glucose ≥100mg/dl or under medication)&#xD;
&#xD;
               3. High blood pressure (≥ 130/85 mmHg or on medication)&#xD;
&#xD;
               4. High triglycerides (≥150 mg/dl or on medication)&#xD;
&#xD;
               5. Low HDL-cholesterol (&lt;40mg/dl in men, &lt;50mg/dl in women)&#xD;
&#xD;
          7. Started diet and exercise interventions, as per treating Investigator's suggestion and&#xD;
             in line with current guidelines within a 4-week window prior to enrolment into the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant alcohol intake &gt;7 standard alcoholic drinks per week (70 g ethanol) in&#xD;
             women and &gt;14 (140 g) in men&#xD;
&#xD;
          2. Received Legalon® or any other hepatoprotective treatment before the allowed 4-week&#xD;
             window prior to enrolment into the study.&#xD;
&#xD;
          3. On diet and exercise before the allowed 4-week window prior to enrolment into the&#xD;
             study.&#xD;
&#xD;
          4. Other concomitant established / diagnosed liver diseases, including chronic hepatitis&#xD;
             B, chronic hepatitis C, autoimmune liver diseases (including autoimmune hepatitis),&#xD;
             celiac disease, primary biliary cholangitis, primary sclerosing cholangitis, biliary&#xD;
             obstruction, drug-induced liver disease (including herbal medicines and dietary&#xD;
             supplements), metabolic liver disorders (such as Wilson's disease, alpha-1-&#xD;
             antitrypsin deficiency, hemochromatosis, glycogen storage disorders, cholesterol&#xD;
             storage disorders), severe liver diseases, non-alcoholic steatohepatitis (NASH) or&#xD;
             other forms of advanced fatty liver disease (including clinically relevant fibrosis,&#xD;
             &gt;F2, or established cirrhosis), liver carcinoma&#xD;
&#xD;
          5. Patients treated with drugs with known hepatotoxic effects (at risk of drug-induced&#xD;
             liver injury [DILI]), including herbal medicines and dietary supplements&#xD;
&#xD;
          6. Other major diseases that, in the treating Investigator opinion, can impair liver&#xD;
             function, as for example type 1 diabetes&#xD;
&#xD;
          7. Pregnant and/or breastfeeding women&#xD;
&#xD;
          8. Persons that, in treating Investigator's opinion, are not able to fulfil study&#xD;
             requirements&#xD;
&#xD;
          9. Persons that refuses to participate&#xD;
&#xD;
         10. Patients that, in the Investigator's opinion, are or have been infected with COVID-19&#xD;
             (i.e. presence/referral of COVID-19 symptoms or positive antigenic/molecular test)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Yeong Yeh, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Hospital Universiti Sains Malaysia,16150 Kelantan Darul Naim, MALAYSIA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sakkarin Chirapongsathorn, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Phramongkutklao Hospital, Bangkok, 40002, Thailand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marilyn Arguillas, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davao Doctors Hospital, Davao City, Philippines 8000</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melanie Emmeluth</last_name>
    <phone>+4961728881194</phone>
    <email>Melanie.Emmeluth@viatris.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sathish Chandran</last_name>
    <phone>+91 80 667 28937</phone>
    <email>Sathish.Chandran@viatris.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silymarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

